Supplemental material
Postgraduate Medicine
Volume 131, 2019 - Issue 4
Open access
22,295
Views
51
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes - Review
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Jaime A DavidsonThe University of Texas Southwestern Medical Center, Touchstone Diabetes Center, Dallas, TX, USACorrespondence[email protected]
View further author information
View further author information
Pages 251-260
|
Received 14 Feb 2019, Accepted 26 Mar 2019, Published online: 14 Apr 2019
Related Research Data
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
Source:
Ovid Technologies (Wolters Kluwer Health)
Health-related quality of life in CKD Patients: correlates and evolution over time.
Source:
American Society of Nephrology (ASN)
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
Source:
American Diabetes Association
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Source:
Massachusetts Medical Society
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
Source:
SAGE Publications
Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
Source:
AACE Corp (American Association of Clinical Endocrinologists)
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Source:
Springer Nature
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Source:
Annual Reviews
DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)
Source:
Elsevier BV
Trends in prevalence of chronic kidney disease in the United States
Source:
American College of Physicians
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Source:
Massachusetts Medical Society
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
Source:
Wiley
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Source:
Springer Science and Business Media LLC
US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States
Source:
Elsevier BV
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Source:
Elsevier BV
DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)
Source:
Elsevier BV
Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease
Source:
Elsevier BV
Epidemiology of Diabetes and Diabetes Complications in the Elderly: An Emerging Public Health Burden
Source:
Springer Nature
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Source:
Elsevier BV
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Source:
Wiley-Blackwell
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY
Source:
AACE Corp (American Association of Clinical Endocrinologists)
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
Source:
Springer Nature
Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes
Source:
American Diabetes Association
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Source:
Springer Science and Business Media LLC
Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial:
Source:
SAGE Publications
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
Source:
Springer Nature
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
Source:
American Medical Association (AMA)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Source:
New England Journal of Medicine (NEJM/MMS)
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
Source:
Ovid Technologies (Wolters Kluwer Health)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
Source:
Wiley-Blackwell
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Source:
New England Journal of Medicine (NEJM/MMS)
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
Source:
Springer Nature
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Source:
Figshare
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
Source:
American Medical Association (AMA)
SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis
Source:
Elsevier BV
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Source:
Springer Nature
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
Source:
Informa Healthcare
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function
Source:
Ovid Technologies (Wolters Kluwer Health)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Source:
Massachusetts Medical Society
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
Source:
Springer Nature
SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
Source:
Figshare
Canagliflozin, an inhibitor of sodium–glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
Source:
Informa Healthcare
Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
Source:
Elsevier BV
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
Source:
American Diabetes Association
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
Source:
American College of Physicians
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
Source:
Springer Nature
Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach
Source:
MDPI AG
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study
Source:
Springer Nature
The economic burden of progressive chronic kidney disease among patients with type 2 diabetes
Source:
Elsevier BV
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Source:
American Society of Nephrology (ASN)
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.